1. A pharmaceutical composition for inhalation containing aclidinium in the form of a dry powder of a pharmaceutically acceptable salt mixed with a pharmaceutically acceptable carrier in the form of a dry powder, which contains a measured nominal dose of aklidinium equivalent to about 200 μg of aklidinium bromide. A pharmaceutical composition according to claim 1 in the form of a single dose formulation in the form of a dry powder containing one measured nominal dose of aklidinium equivalent to about 200 μg of aklidinium bromide. The pharmaceutical composition of claim 1 in the form of a multi-dose dry powder formulation for administration with a multi-dose dry powder inhaler device that is calibrated to provide a metered nominal dose of aklidinium equivalent to about 200 μg of aklidinium bromide. A pharmaceutical composition according to one of the preceding claims, wherein the pharmaceutically acceptable salt of aklidinium is aklidinium bromide. The pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable carrier is lactose particles. The pharmaceutical composition according to claim 1, in which the mass ratio of aklidinium and carrier is from 1:50 to 1: 150.7. The pharmaceutical composition according to claim 6, in which the mass ratio of aclidinium and carrier is from 1: 100 to 1: 150.8. A pharmaceutical composition according to claim 1, wherein the average particle diameter of aklidinium is 2-5 microns. The pharmaceutical composition of claim 1, wherein the carrier particles are characterized by a d10 value of 90-160 μm, a d50 value of 170-270 μm, and a d90 value of 290-400 μm. The pharmaceutical composition according to claim 1, which contains1. Фармацевтическая композиция для ингаляции, содержащая аклидиний в форме сухого порошка фармацевтически приемлемой соли в смеси с фармацевтически приемлемым носителем в форме сухого порошка, которая содержит отмеренную номинальную дозу аклидиния, эквивалентную примерно 200 мкг аклидиния бромида.2.
